Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171567 | 0.85 | EGFR (0.47) | PIN1MAOBPOLBHSP90AA1MAPT | |
| SCHEMBL30635854 | 0.85 | EGFR (0.47) | PIN1MAOBPOLBHSP90AA1MAPT | |
| SCHEMBL9945495 | 0.83 | PIN1 (0.47) | PIN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL30672854 | 0.83 | POLB (0.53) | PIN1MAOBPOLBHSP90AA1MAPT | |
| SCHEMBL9945481 | 0.83 | PIN1 (0.47) | PIN1MAOBPOLBHSP90AA1MAPT | |
| SCHEMBL1032316 | 0.83 | PIN1 (0.63) | PIN1MAOBMAPTF10ALDH1A1 | |
| SCHEMBL16706312 | 0.83 | POLB (0.53) | PIN1MAOBPOLBHSP90AA1MAPT | |
| SCHEMBL31547647 | 0.82 | PIN1 (0.60) | PIN1POLBMAPTALDH1A1CASP6 | |
| SCHEMBL17544398 | 0.82 | PIN1 (0.60) | PIN1POLBMAPTALDH1A1CASP6 | |
| SCHEMBL30672829 | 0.81 | PIN1 (0.51) | PIN1MAOBPOLBMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012061299-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | ABCG2, CYP3A5, CYP3A43 | PIN1 90/4885MAOB 82/4885POLB 3621/4885 |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PIN1 90/4885MAOB 82/4885POLB 3621/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PIN1 90/4885MAOB 82/4885POLB 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.